The Open
Prostate Cancer Journal
ISSN: 18768229 



[DOI: 10.2174/1876822901205010015]
Impact of Percentage of Positive Biopsy Cores on
Biochemical Outcome in Patients Treated With LowDose Rate
(Iodine125) Brachytherapy for Prostate Cancer
C. Yuen, T. Hossack, A.M. Haynes, R.A. Pe Benito, J. Matthews,
G. Fogarty, R. Jagavkar, P. Brenner and P. Stricker
Pp 1519
• To investigate the significance of the percentage of
positive biopsy cores (PPBCs) in predicting the biochemical
outcome in patients with clinically localised prostate
cancer undergoing lowdose rate brachytherapy (LDRB).
• A total of 326 consecutive patients underwent LDRB between February 1997
and January 2007. The cohort consisted of 68.7%, 30.4% and
0.9% of low, intermediate and highrisk groups
respectively as defined by the D'Amico classification.
Patients were stratified according to PPBCs (<35%, 3550%,
>50%)
• Of the 326 men, 316 (97%) met the study criteria and
were included in the analysis. The median followup was 66.3
(12.9147.5) months. Thirtyeight men (12%) developed
evidence of biochemical relapse as defined by the Phoenix
definition at a median of 44.5 (4133) months. The overall
5year and 10year biochemical relapsefree rate (BRFR) was
91.9% (95% CI 87.9% to 94.6%) and 76.9% (95% CI 66% to 84%)
respectively.
• On univariate analysis, Gleason score (p=0.03), D'Amico risk groups
(p=0.004) and PPBCs (p=0.001) were significant predictors of
biochemical failure. In the multivariate model, the PPBCs
(p=0.0006) and pretreatment PSA (p=0.004) were the only
variables that predicted for biochemical failure. The 5year
biochemical relapsefree rate was 93.5%, 93.0% and 76.5% for
the PPBCs <35%, 35%50% and >50% respectively (p=0.001).
• The PPBC is an important independent predictor of the
5year biochemical relapsefree survival after LDRB. This
finding suggests that patients with high volume tumour are
at increased risk of biochemical failure with LDRB.
Back
